Tag: AF symposium 2026
Pulse Biosciences presents latest data from first-in-human study evaluating nPulse cardiac...
Pulse Biosciences has announced late-breaking clinical data from the nPulse cardiac catheter first-in-human feasibility study, demonstrating the successful treatment of atrial fibrillation (AF) across...
Atraverse showcases findings indicating mitigated left atrial injury and reduced RF...
Atraverse Medical has announced the presentation of new clinical and preclinical data at the 2026 AF symposium (5–7 February, Boston, USA), further validating the...
Abbott announces late-breaking data from global VOLT-AF and FOCALFLEX studies
Abbott has announced new clinical data from two late-breaking presentations at the 2026 AF symposium (5–7 February, Boston, USA) that demonstrate the safety and efficacy...
Argá Medtech reports 94% lesion durability and “strong safety profile” with...
Argá Medtech has announced positive clinical results from the BURST-AF first-in-human trial, demonstrating the safety, effectiveness and durability of its Coherent sine-burst electroporation (CSE)...
Field Medical presents late-breaking Field PULSE trial data at 2026 AF...
Field Medical has announced the presentation of late-breaking clinical trial data from the first-in-human Field PULSE study—which is evaluating the company’s FieldForce ablation system...
J&J presents early outcomes from OMNY-AF pilot study alongside new Varipulse...
Johnson & Johnson (J&J) has announced 12-month pilot-phase data from the OMNY-AF study evaluating its investigational Omnypulse platform for the treatment of symptomatic paroxysmal...
Volta Medical’s RESTART trial provides “promising findings” on AI solutions in...
Volta Medical has announced results from the RESTART trial, published in the journal Heart Rhythm, that demonstrate positive outcomes for patients with recurrent atrial fibrillation...